INAB stock forecast, quote, news & analysis
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases... Show more
Why IN8bio (INAB) Stock Is Down 32% in the Last 30 Days
Key Takeaways
- INAB shares declined roughly 32% over the trailing 30 days, retreating from an early-October high near $1.46 to about $0.96.
- The pullback reversed a strong multi-week advance and unfolded on unusually thin trading volumes, a pattern consistent with micro-cap biotech volatility rather than a single fundamental catalyst.
- Over the latest quarter, shares were roughly flat but swung widely between approximately $0.88 and $1.46.
- IN8bio remains a clinical-stage developer of gamma-delta (γδ) T cell therapies, with lead programs in glioblastoma (INB-200/400) and leukemia (INB-100).
- Analyst coverage remains constructive, with a consensus Moderate Buy rating and price targets well above the current share price.
- Key items to monitor include FDA regulatory guidance, additional glioblastoma survival data, and the company's cash position.
- For deeper context, explore IN8bio's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven strategies are approaching stocks like this one.
IN8bio (INAB) Company Overview and Market Position
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases. Its lead pipeline is anchored by INB-200 and INB-400, autologous, genetically modified "DeltEx DRI" γδ T cell candidates for newly diagnosed glioblastoma (GBM); INB-100, an allogeneic γδ T cell candidate for high-risk leukemias undergoing haploidentical stem cell transplantation; and INB-600/INB-619, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications.
As a pre-revenue, development-stage company, IN8bio generates no product sales and funds operations primarily through equity financing. Investors follow the stock for its exposure to a differentiated cell-therapy platform, its published clinical data in GBM, and upcoming regulatory and data milestones. With a market capitalization of roughly $10 million and fewer than 10 million shares outstanding, the stock is a low-liquidity micro-cap whose price can move sharply on modest trading activity.
IN8bio (INAB) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, INAB shares fell approximately 32%, declining from a closing price of about $1.40 in early October to roughly $0.96. The stock touched an intraday high near $1.46 at the start of the period before giving back those gains through a steady October selloff that carried shares as low as about $0.87.
The latest quarter paints a more mixed picture. From a level near $0.96 at the start of the three-month period, shares first dipped to a low around $0.88 in mid-August, then rallied to approximately $1.46 in early October before retreating back toward $0.96. The result was a quarter that was roughly flat on a net basis but highly volatile, reflecting shifting sentiment in a thinly traded clinical-stage name.
What Drove INAB Stock Price in the Last 30 Days
The 30-day decline did not stem from a single dominant negative announcement. Instead, shares reversed from an early-October peak after a sharp run-up, in an environment of thin trading. Several sessions posted volumes of only a few thousand shares, amplifying price swings.
Among the limited news flow, H.C. Wainwright reiterated a Buy rating with a $6.00 price target in early October, while Weiss Ratings reiterated a "Sell" rating in mid-October, reflecting the wide divergence in views that often surrounds early-stage biotechs. The company also announced routine equity inducement grants, a minor source of dilution that some investors watch closely in cash-burning, pre-revenue issuers. With no near-term clinical readout scheduled during the period, shares were susceptible to profit-taking and general weakness in the small-cap biotech space.
What Drove INAB Stock Performance Over the Last Quarter
The broader three-month trend was defined by a strong rally followed by a sharp reversal. Positive catalysts earlier in the period included the peer-reviewed publication of INB-200 Phase 1 data in The Journal of Clinical Oncology, which reported that repeat-dose patients achieved a median progression-free survival of 16.1 months versus a roughly 6.9-month standard-of-care benchmark, and updated glioblastoma survival data presented at the 2026 ASCO Annual Meeting. These milestones, together with sustained analyst coverage, supported the advance from August lows toward October highs.
The subsequent pullback reflected the absence of new catalysts to sustain momentum, thin trading liquidity, and the ongoing cash needs typical of a clinical-stage company, rather than any reported deterioration in the underlying science.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader universe that spans hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies are surfaced in this section. The bots vary by strategy, timeframe, and performance metrics, allowing users to compare different approaches side by side. For traders interested in how algorithmic strategies are positioning around volatile names like IN8bio, the page offers a practical starting point for evaluating AI-driven signals and historical performance.
INAB Stock Forecast Drivers: What Investors Should Watch Next
Several catalysts may shape IN8bio's outlook. Management has guided toward FDA feedback on a potential regulatory pathway for its DeltEx DRI glioblastoma program in the second half of 2026, along with additional GBM clinical updates, including final overall survival data. The company has also indicated it expects initial preclinical animal data and IND-enabling data for INB-619 and long-term follow-up results from the INB-100 leukemia program at a medical meeting in late 2026.
Beyond clinical milestones, investors will likely monitor the company's cash runway and any financing activity, given its pre-revenue status. With shares trading below $1.00, market participants may also watch for any Nasdaq minimum bid price compliance considerations. These factors, together with broader small-cap biotech sentiment, will be central to how the stock trades in the period ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for INAB turns negative, indicating new downward trend
INAB saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 81 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for INAB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 43 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
INAB moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INAB crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for INAB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INAB's RSI Oscillator exited the oversold zone, 32 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 68 cases where INAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +13.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where INAB advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.497) is normal, around the industry mean (3.498). P/E Ratio (-0.713) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. INAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology